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In recent years, progress has been made in the characterization of natural killer (NK) cells 
in lung malignancies, and we have now gained a better understanding of the frequency, 
localization, phenotype, and functional status of NK cells infiltrating these tumors. NK cell 
subset recruited in lung cancer is mainly capable of producing relevant cytokines rather 
than exerting direct cancer cell killing. Thus, the relevance of NK cells in tumor microen-
vironment might also go beyond the killing of tumor cells, being NK cells endowed with 
regulatory functions toward an ample array of immune effectors. Nevertheless, boosting 
their cytotoxic functions and redirecting the migration of cytotoxic NK cell subset to the 
tumor site might open new therapeutic avenues for lung cancer. Also, we believe that a 
deeper investigation into the impact of both conventional (e.g., chemotherapy) or new 
therapies (e.g., anti-immune checkpoints mAbs) on NK cell homeostasis in lung cancer 
patients is now required.
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Several lines of evidence support the notion that natural killer (NK) cells play an important role in 
the control of tumor growth. Notably, along with the large array of results derived from experimental 
mouse models, a reduced NK cell lytic activity has been associated in human with an increased risk 
of cancer. Nevertheless, only a very limited number of NK cells can be detected within the majority 
of human solid tumors.
The discovery that NK cell can easily recognize and lyse tumor cells, immediately translated into 
hope that NK cells might find a place in the clinic as therapeutic tools. Extensive efforts have been 
made to exploit NK cells into the clinic and many of these attempts have mainly relayed on knowl-
edge obtained by studying peripheral blood (PB) NK  cells. However, the environmental context 
and cytokine milieu in which NK cells are present, and perceive potential activating signals, may 
strongly impact on their ultimate effector activity, thus offering one of the possible explanations of 
the inconsistent outcomes of the majority of NK cell-based therapies. As a matter of fact, several 
studies have aimed to investigate the biology of NK cells present within the neoplastic tissue and 
the clinical relevance of this infiltrate: in this context, lung cancer, the main cause of cancer-related 
mortality, represents a major topic for studying the anti-tumoral role of NK cells.
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NK ceLLs iN LUNG cANcer AND tHeir 
cLiNicAL siGNiFicANce
The impact of NK cells as a potential prognostic marker in resected 
NSCLC still remains an open question. Although some early 
studies have demonstrated that the presence of NK cells in the 
immune infiltrate was associated with a lower risk of relapse and/
or longer survival (1, 2), these analyses may now be considered 
incomplete or not exhaustive because of the use of markers not 
exclusively expressed by NK cells. Indeed, a more specific analysis 
of this aspect recently failed to find an association between the 
presence of NKp46+ NK cells at early stages of the disease with the 
clinical outcome (3). However, another recent report showed that 
the number of NK cell infiltrating lung cancer tissue (detected as 
CD56+CD16+ cells) positively correlated to the survival of lung 
cancer patients (4).
Although the clinical significance of NK cells in lung cancers 
seems to require more work, our knowledge about the features of 
NK cells infiltrating NSCLC has expanded considerably in recent 
years. A certain consensus has been reached regarding the evi-
dence that NK cells associated to the immune infiltrate of NSCLC 
are quite different from those normally found in the non-tumor 
areas of the lungs (5–7), since normal lungs are mainly popu-
lated by CD56dim NK cells, whereas tumors are mainly enriched 
in CD56bright NK  cell subset. Overall, the NK  cell population 
found within NSCLC has been described as displaying profound 
alterations in the expression of relevant NK  cell receptors, 
more specifically, downregulation of activating (NKp30, NKp80, 
CD16, DNAM-1) and inhibitory (ILT-2 and KIRs) receptors, as 
well as upregulation of NKG2A when compared to the normal 
counterpart (3). Functionally, intratumoral NK  cells displayed 
impairments in the ability to both degranulate (8) and produce 
IFNγ (3) in response to classical NK cell targets, and they may 
rather acquire a proangiogenic phenotype due to the tumor 
microenvironment (TM) (9).
Nevertheless, these conclusions were mainly drawn by con-
sidering the NSCLC-infiltrating NK cells as a whole population. 
Recent reports suggested that expression of markers such as 
CD69, CD103, and CD49a can distinguish tissue resident from 
circulating NK cells (10). These advances indicate the necessity 
to revise our previous data and call for a thorough investigation 
of the various NK  cell subsets infiltrating lung tumors. In this 
regard, high levels of CD69 have been observed on intratumoral 
NK cells (8) (interpreted as activation marker, at that time) when 
compared to matched non-tumoral lung tissues, thus suggesting 
that a substantial amount of NK cells may be actually retained 
within the TM upon migration (or alternatively upon in  situ 
development). Along with CD69, CD103 has also been found to 
be expressed on a subset of NKp46+ cells within the TM (although 
potentially co-expressed by ieILC1) [(11) and personal observa-
tions by P. Carrega]. These observations propel new questions 
about the specific contribution of tissue-resident NK  cells in 
lung tumor immunosurveillance as well as about their activity in 
already established tumors.
A relative abundance of CD56bright NK  cells was also 
observed in pleural effusions (PEs) from different type of 
primary and metastatic tumors. In contrast with NK  cells 
isolated from solid lung cancer tissues, PE-NK cells express 
normal levels of both main activating receptors and MHC 
Class I-specific inhibitory receptors and they rapidly release 
cytokines upon exposure to neoplastic cells (12). These data 
further confirm how the microenvironment and cytokine 
milieu of lung cancer can exert a strong influence on NK cell 
effector activities (13, 14).
AccUMULAtiON OF cD56bright NK ceLLs 
At tHe tUMOr site
Overall, current data show that NK  cells are very rare within 
human NSCLC, and this evidence is in accordance with parallel 
observations in other solid tumors. Similarly to other tumors, 
NSCLC-infiltrating NK  cells resemble PB-CD56bright in their 
phenotype. These data raise various questions about the actual 
function of this “regulatory” NK  cell subset at the tumor site. 
Primarily, whether the enrichment of CD56bright NK cells in lung 
tumors represents a preferential recruitment of these cells from 
PB or adjacent tissues or rather a local expansion of immature 
NK  cells within the tumor. Recent findings have revealed that 
tumor microenvironment may play a role in this specific accumu-
lation. In particular, comparison of gene expression data between 
neoplastic and healthy lung tissues showed a chemokine switch 
(occurring upon neoplastic transformation) that is in agreement 
with the accumulation of non-cytotoxic CD56bright NK  cells 
recruited from PB (6). Specifically, variations in the tumor tis-
sues involved a significant downregulation of CXCL2 that can 
selectively attract CD56dim NK cells and, vice versa, an upregula-
tion of chemokines specific for CCR7 and CXCR3 receptors (i.e., 
CCL19, CXCL9, and CXCL10), which are, on the contrary, pref-
erentially expressed by CD56bright NK cells. This might represent 
a further mechanism of cancer immunoediting with implications 
for both immunosurveillance and tumor escape from NK  cell 
attack. Remarkably, also breast cancer, another tumor type char-
acterized by enrichment in non-cytotoxic CD56bright NK  cells, 
displayed upregulation of genes coding for chemokines attract-
ing this subset, when compared with gene expression profile of 
healthy breast tissues. Since NSCLC are often associated with 
the presence of intratumoral tertiary lymphoid structures (15), 
it is conceivable that these ectopic lymphoid tissues, as well as 
the establishment of a lymphoid-like stroma within the tumor, 
might drive the expression of chemokines normally secreted in 
secondary lymphoid organs (CCL19, CCL21, etc.) and, therefore, 
preferentially attract CD56bright non-cytotoxic NK  cells at the 
tumor site (Figure 1). An experimental approach employing the 
use of humanized mice xenograft models in which the xenograft 
develops in the context of a human immune system might 
potentially help in answering the question on which NK  cell 
subset preferentially migrate to the neoplastic tissues and to shed 
further light on the mechanisms lying behind their migratory 
properties.
On the other hand, however, a local expansion of less mature 
NK cells in the tumor cannot be excluded. In agreement with 
this hypothesis, it has been reported that a significant amount 
FiGUre 1 | Natural killer (NK) cell subsets in healthy and neoplastic lung tissues. Human healthy lung tissues are mainly populated by CD56dimCD16+ 
NK cells but also present a small subset of CD56bright NK cells expressing CD69, a marker of tissue-residency. Conversely, NSCLC tissues were found to be 
infiltrated by an NK cell population highly enriched in CD56brightCD16negPerforinlow/negKIR+ cells. The reasons for such an accumulation are not clear. They may derive 
from (1) extravasation of PB NK cells from newly formed blood vessels and/or (2) migration of CD56bright NK cells from the adjacent normal lung tissue in response to 
upregulated chemokines (CXCL9/CXCL10) in the neoplastic tissues. Moreover, (3) they may be recruited by chemokines (such as CCL19/CCL21) expressed in 
tertiary lymphoid structures or a lymphoid-like stroma via high endothelial venules (HEV), which represent a new gateway for lymphocyte entry into the tumor. Finally, 
(4) a local expansion from NK cell precursors (NKP) (21)/immature NK cells cannot be excluded. Noteworthy, the ratio of tissue-resident versus circulating/
non-residing NK cells in neoplastic tissue has so far not sufficiently been deeply investigated.
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of CD56brightperforinnegCD16low NK cells infiltrating lung cancers 
(and breast cancer) showed upregulation of KIRs on their 
surface (8, 16). These observations support the hypothesis that 
TM might, at least in some cases, might favor the expansion of 
functional intermediate of the normal differentiation between 
the CD56bright and CD56dim human NK-cell subsets (17, 18). 
Thus, as previously shown in in  vitro studies (17), CD56bright 
NK  cells might locally proliferate and eventually differentiate 
into the cytotoxic counterpart under adequate stimuli obtained 
within TM.
It is noteworthy that the analysis of perforin expression results 
critical in this context for identifying the two main distinct subsets 
of NK cells, since the intratumoral CD56brightCD16neg NK cell phe-
notype could also represents the result of an activation-induced 
upregulation of CD56 and concomitant cleavage of CD16 by 
the ADAM17 protease (19, 20). Finally, we cannot exclude the 
possibility that tumor-infiltrating NK  cells can originate from 
NK cell progenitors migrated to the tumor site (Figure 1). This 
hypothesis is supported by the recent discovery, in various 
human adult peripheral tissues, of an NK cell-restricted precur-
sor (defined as Linneg CD34+ CD38+ CD123neg CD45RA+ CD7+ 
CD10+ CD127neg) able to give rise to both CD56dim and CD56bright 
NK cells in vitro and in vivo and expressing high levels of CD62L 
on their surface (21).
FUNctiONs OF NK ceLLs iN  
NscLc MicrOeNvirONMeNt
Collectively, we know relatively little about the factors that regulate 
NK cell response under different physio-pathological conditions; 
therefore, the potential activity of NK cells in lung cancer micro-
environment can just be speculative. The notion that CD56bright 
NK cells are a subset endowed with immunoregulatory properties 
is now in general accepted: this is related to their ability to secrete 
cytokines able to influence innate immunity as well as to their 
ability to assist in the polarization of primary adaptive immune 
responses in secondary lymphoid organs. However, in the context 
of human cancers, they may even exert an immune suppressive 
function. As a matter of fact, the CD56bright CD16lowKIR+/− pheno-
type found in lung cancers is also reminiscent of NK cells present 
in decidua tissue and it might be induced upon NK  cell entry 
into a tumor microenvironment expressing substantial TGFβ 
(22). Also, results from a recent investigation in melanoma are in 
line with a potential regulatory role by CD56bright NK cells (23). 
According to this study, blood CD56brightCD16neg NK cells express 
higher levels of ectoenzymes than CD56dim NK cells; hence, they 
may act as “regulatory cells” by inhibiting autologous CD4+ 
T  cell proliferation. This activity is mediated by production of 
adenosine, with a pivotal role played by CD38. Moreover, upon 
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proper activation, CD56bright NK  cells are equally, if not more, 
cytotoxic than CD56dim NK  cells against autologous activated 
CD4+ T cells (24). This observation may be of interest in NSCLC, 
where NK cells were mainly found in the tumor stroma, in close 
contact with other leukocytes (8). It should be noted that also 
NK cells from PE, upon IL-2 activation, gain a strong cytolitic 
activity against tumor cells (12), even stronger than PB-NK cells 
undergoing the same activation. These findings raise new ques-
tions about a suitable therapeutic exploitation of NK cells: more 
specifically, about the possibility to boost cytotoxic function of 
CD56bright NK cells against cancer cells while avoiding elimination 
of activated autologous CD4+ T cells.
As a whole, however, few in vivo data have so far been col-
lected in support of an immunosuppressive role of NK  cells 
within tumor tissues and in lung cancer in particular. 
Nevertheless, this remains an interesting and poorly explored 
field of investigation.
On the other hand, NK  cells have been implicated in the 
response to tumors also because of their abundant release of 
IFNγ. Experimental animal studies highlighted the importance 
of NK  cell-mediated secretion of IFNγ in tumor rejection. In 
particular, the initial expression of IFNγ by NK cells may induce 
expression of CXCR3 ligands and, in turn, contribute to further 
accumulation of NK  cells and tumor rejection (25). Tu et  al. 
showed a pivotal role for CD160 and IFNγ secretion in control-
ling tumor growth by NK cells (26). An early release of IFNγ may 
be of relevance also for upregulating co-stimulatory molecules on 
dendritic cell (DC) surface, endowing DCs with a more potent 
triggering potential for tumor-specific CD8+ T cells (27), but also, 
as highlighted below, for the expression of ligands of immune 
inhibitory receptors.
rOLe OF NK ceLLs iN cONveNtiONAL 
AND UNcONveNtiONAL ANticANcer 
tHerAPY
The role of NK cells in the conventional therapy of lung cancer is 
only partially known; in addition, the possible modifications of 
NK cell activities and homeostasis upon administration of thera-
pies currently used for lung cancers, ranging from conventional 
chemotherapy to anti-PD1 blocking mAbs, have been thus far 
scarcely investigated. Nevertheless, various evidences support the 
notion that beneficial effects of conventional therapies may also 
be mediated as “off-target” mechanisms by this innate immune 
cell population. For example, both cisplatin (28) and gemcitabine 
treatments (29) induce upregulation of NKG2D ligands on cancer 
cells. Similarly, also inhibitors of the MEK/ERK signaling path-
way can upregulate the expression of ULBP2, one of the ligand 
of NKG2D, by inducing demethylation of the ULBP2 promoter 
(30). Moreover, NK cells may contribute to the efficacy of targeted 
therapies, such as cancer-associated fibroblast-targeted therapy 
used in combination with DC-based vaccines (31), or agents 
targeting EGFR, such as erlotinib (32) and necitumumab. The 
latter has been approved as a first-line treatment for advanced 
squamous NSCLC, the less immunogenic type of NSCLC tumor. 
Interestingly, the necitumumab–EGFR complex can induce 
ADCC by various types of immune system cells, such as NK 
lymphocytes (33).
In light of the therapeutic benefit obtained with immune 
checkpoint inhibitors, such as mAbs blocking programed cell 
death protein 1 (PD1) pathway, it would be interesting to further 
investigate the effects of these classes of drugs on NK cell com-
partment. Anti-PD1 (nivolumab and pembrolizumab), anti-KIR 
(lirilumab), and anti-NKG2A (monalizumab) may act by remov-
ing a brake on the effector functions of NK cells. Anti-PD1 agents 
have been already approved for the treatment of advanced NSCLC 
and, very recently, have shown promising results when used in 
the neoadjuvant setting (34). Anti-PD1 therapy might unleash 
the cytotoxic potential of activated NK cells expressing PD1 (35), 
thus contributing to the anticancer activities of this drug. On the 
other hand, NK cells might also be detrimental for avoiding PD1 
blocking since IFNγ derived from tumor-infiltrating NK  cells 
may further increase the expression of the ligand PD-L1 in the 
tumor microenvironment.
While we are now accomplishing groundbreaking results 
by anti-PD1 agents, anti-KIR agents are currently in phase II; 
nonetheless, they may be important in various settings, in neo-
adjuvant and advanced settings but also as adjuvant therapy in 
order to reduce risks of recurrence. Along with KIRs, targeting 
of the inhibitory receptor NKG2A (monalizumab) is currently 
under investigation as single agent or in combination with other 
agents in different types of solid tumors (36). The rationale for 
the use of this agent in lung cancer is also supported by the 
higher expression levels of NKG2A in intratumoral NK  cells 
if compared to NK cells in normal lung tissues (6, 8). Another 
therapy targeting the inhibitory receptor LAG3 (BMS-986016), 
expressed on lymphocytes and NK  cells, is also currently 
investigated (NCT01968109) alone and in combination with 
nivolumab in subjects with select advanced (metastatic and/
or unresectable) solid tumors. Further increasing the number 
of targetable checkpoints on NK  cells, recent preclinical data 
demonstrated the utility of blocking CD96 for enhancing 
NK cell activity against experimental and spontaneous metas-
tases (37). Finally, targeting costimulatory receptors such as 
CD137 (4-1BB), expressed on activated NK cells and cytotoxic 
T cells, may represent another option, especially in combination 
with mAbs targeting TAA, as shown for head and neck cancer 
patients (38).
cONcLUsiON AND PersPective
Despite knowledge on NK  cell biology significantly increased 
in these last years, we surprisingly still know relatively little 
about their functions in TM. This is particularly astonishing 
considering that NK cell discovery was related to their strong 
ability to recognize and kill cancer cells without prior sensitiza-
tion. Clearly, further knowledge, particularly in human setting, 
is required to better exploit this abundant innate lymphocyte 
population in lung cancer treatment. However, recent evi-
dences indicate that CD56bright NK  cell population infiltrating 
lung cancers, endowed with low ability to kill cancer cells, can 
spontaneously acquire KIR receptors and thus further differ-
entiate, suggesting that they might convert in cytotoxic killer 
AB
C
FiGUre 2 | Possible conversion of lung cancer-infiltrating natural killer (NK) cells into highly cytotoxic killer cells upon administration of NK-
activating drugs. (A) NK cells isolated from NSCLC tissues display phenotypic features similar to those of peripheral blood (PB) CD56bright NK cells, with the 
exception of KIRs, that can be detectable on these cells. Similarly to PB CD56bright NK cells, they are endowed with high proliferative potential but impaired in their 
cytotoxic capability. In addition, it is not clear whether NK cells infiltrating human lung tumors express other immune checkpoints (such as PD-1), which might further 
contribute to their poor cytolytic activity. (B) Upon activation with stimulating cytokines (recombinant IL-15, IL-2) or mAbs-blocking inhibitory receptors (e.g., 
anti-NKG2A, which is highly expressed on these cells, or anti-PD1), intratumoral NK cells may proliferate in situ and modify their phenotype acquiring strong cytolytic 
capabilities against cancer cells. (c) Administration of cytokines or other NK-activating drugs, currently available, can upregulate the expression of cytolytic granules 
on expanded tumor-infiltrating NK cells but also induce higher levels of KIR inhibitory receptors: this might be circumvented by administration of anti-KIRs mAbs. It 
remains to be investigated whether in vivo stimulation of lung cancer-infiltrating NK cells can upregulate on these cells the expression of activating receptors (e.g., 
CD16), immune checkpoints, or markers of tissue residency.
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cells. Remarkably, CD56bright NK cells, the main NK cell subset 
infiltrating lung cancer, can undergo robust proliferation upon 
appropriate cytokine stimulation. At the same time, factors able 
to efficiently activate NK  cells, induce their proliferation and 
to terminally differentiate them into highly cytotoxic NK cells 
are currently available as clinical-grade agents (e.g., IL-15 and/
or mAbs blocking NK inhibitory receptors) (Figure 2). Finally, 
although few data are currently available, we recently started 
to shed some light on the mechanisms ruling he recruitment 
of NK cells within lung cancer tissues. The use of factors able 
to modify lung cancer expression of chemokines involved in 
NK cell recruitment could represent an interesting therapeutic 
avenue.
While further basic investigation on the biology of lung cancer 
NK cells is clearly required, we recently gained a better insight in 
this field. Novel immunotherapeutic strategies for lung cancers, 
conceivably in combination with established anticancer therapies, 
should now aim at increasing the amount of cytotoxic NK cells 
in lung cancers: that could be achieved not only recruiting them 
from PB but also driving their proliferation and differentiation 
within TM.
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